The role of phospholipase Cγ1 in breast cancer and its clinical significance

What is it about?

One of the major problem occurring to breast cancer patients is to know whether they are at low or high risk of reappearance of the tumour upon first treatment. The ability to distinguish between these two group of patients may have important implications to improve treatment outcomes. In this review, we discuss the potential use of the enzyme phospholipase Cγ1 as a potential predictive factor and a therapeutic target.

Featured Image